Literature DB >> 29967027

Is It Time for Systematic Voriconazole Pharmacogenomic Investigation for Central Nervous System Aspergillosis?

Fanny Lanternier1,2, Olivier Lortholary3,2, François Danion1,4, Vincent Jullien5, Claire Rouzaud1, Manal Abdel Fattah6, Simona Lapusan7, Romain Guéry1, Naïke Bigé8, Marjolaine Morgand1, Nicolas Pallet9.   

Abstract

Voriconazole is the standard treatment for invasive aspergillosis but requires therapeutic drug monitoring to optimize therapy. We report two cases of central nervous system aspergillosis treated with voriconazole. Because of low trough plasma concentrations, we identified gain-of-function mutations in CYP2C19 that were partially responsible for the therapeutic failure of voriconazole. We suggest that systematic voriconazole pharmacogenomic investigation of cerebral aspergillosis be performed to avoid effective therapy delay in this life-threatening disease.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  CYP2C19; cerebral aspergillosis; metabolizer; pharmacogenomics; therapeutic drug monitoring; voriconazole

Mesh：

Substances：

Year:  2018        PMID： 29967027      PMCID： PMC6125540          DOI： 10.1128/AAC.00705-18

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  10 in total

1.  Utility of voriconazole therapeutic drug monitoring: a meta-analysis.

Authors:  Me-Linh Luong; Mona Al-Dabbagh; Andreas H Groll; Zdenek Racil; Yasuhito Nannya; Dimitra Mitsani; Shahid Husain
Journal:  J Antimicrob Chemother       Date:  2016-05-10       Impact factor: 5.790

2.  Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy.

Authors:  B Moriyama; A Owusu Obeng; J Barbarino; S R Penzak; S A Henning; S A Scott; Jag Agúndez; J R Wingard; H L McLeod; T E Klein; S J Cross; K E Caudle; T J Walsh
Journal:  Clin Pharmacol Ther       Date:  2017-04-18       Impact factor: 6.875

3.  Utilization of omeprazole to augment subtherapeutic voriconazole concentrations for treatment of Aspergillus infections.

Authors:  Natalie K Boyd; Cindy L Zoellner; Mark A Swancutt; Kavita P Bhavan
Journal:  Antimicrob Agents Chemother       Date:  2012-08-13       Impact factor: 5.191

4.  Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial.

Authors:  Johan A Maertens; Issam I Raad; Kieren A Marr; Thomas F Patterson; Dimitrios P Kontoyiannis; Oliver A Cornely; Eric J Bow; Galia Rahav; Dionysios Neofytos; Mickael Aoun; John W Baddley; Michael Giladi; Werner J Heinz; Raoul Herbrecht; William Hope; Meinolf Karthaus; Dong-Gun Lee; Olivier Lortholary; Vicki A Morrison; Ilana Oren; Dominik Selleslag; Shmuel Shoham; George R Thompson; Misun Lee; Rochelle M Maher; Anne-Hortense Schmitt-Hoffmann; Bernhardt Zeiher; Andrew J Ullmann
Journal:  Lancet       Date:  2015-12-10       Impact factor: 79.321

5.  Low prevalence of resistance to azoles in Aspergillus fumigatus in a French cohort of patients treated for haematological malignancies.

Authors:  Alexandre Alanio; Emilie Sitterlé; Martine Liance; Cécile Farrugia; Françoise Foulet; Françoise Botterel; Yosr Hicheri; Catherine Cordonnier; Jean-Marc Costa; Stéphane Bretagne
Journal:  J Antimicrob Chemother       Date:  2010-12-05       Impact factor: 5.790

6.  Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.

Authors:  Raoul Herbrecht; David W Denning; Thomas F Patterson; John E Bennett; Reginald E Greene; Jörg-W Oestmann; Winfried V Kern; Kieren A Marr; Patricia Ribaud; Olivier Lortholary; Richard Sylvester; Robert H Rubin; John R Wingard; Paul Stark; Christine Durand; Denis Caillot; Eckhard Thiel; Pranatharthi H Chandrasekar; Michael R Hodges; Haran T Schlamm; Peter F Troke; Ben de Pauw
Journal:  N Engl J Med       Date:  2002-08-08       Impact factor: 91.245

7.  Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline.

Authors:  A J Ullmann; J M Aguado; S Arikan-Akdagli; D W Denning; A H Groll; K Lagrou; C Lass-Flörl; R E Lewis; P Munoz; P E Verweij; A Warris; F Ader; M Akova; M C Arendrup; R A Barnes; C Beigelman-Aubry; S Blot; E Bouza; R J M Brüggemann; D Buchheidt; J Cadranel; E Castagnola; A Chakrabarti; M Cuenca-Estrella; G Dimopoulos; J Fortun; J-P Gangneux; J Garbino; W J Heinz; R Herbrecht; C P Heussel; C C Kibbler; N Klimko; B J Kullberg; C Lange; T Lehrnbecher; J Löffler; O Lortholary; J Maertens; O Marchetti; J F Meis; L Pagano; P Ribaud; M Richardson; E Roilides; M Ruhnke; M Sanguinetti; D C Sheppard; J Sinkó; A Skiada; M J G T Vehreschild; C Viscoli; O A Cornely
Journal:  Clin Microbiol Infect       Date:  2018-03-12       Impact factor: 8.067

8.  Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.

Authors:  Thomas F Patterson; George R Thompson; David W Denning; Jay A Fishman; Susan Hadley; Raoul Herbrecht; Dimitrios P Kontoyiannis; Kieren A Marr; Vicki A Morrison; M Hong Nguyen; Brahm H Segal; William J Steinbach; David A Stevens; Thomas J Walsh; John R Wingard; Jo-Anne H Young; John E Bennett
Journal:  Clin Infect Dis       Date:  2016-06-29       Impact factor: 9.079

9.  Impact of CYP2C19 genetic polymorphisms on voriconazole dosing and exposure in adult patients with invasive fungal infections.

Authors:  Fabien Lamoureux; Thomas Duflot; Jean-Baptiste Woillard; David Metsu; Tony Pereira; Patricia Compagnon; Hélène Morisse-Pradier; Mona El Kholy; Luc Thiberville; Jana Stojanova; Christian Thuillez
Journal:  Int J Antimicrob Agents       Date:  2015-12-21       Impact factor: 5.283

Review 10.  Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology.

Authors:  H Ruth Ashbee; Rosemary A Barnes; Elizabeth M Johnson; Malcolm D Richardson; Rebecca Gorton; William W Hope
Journal:  J Antimicrob Chemother       Date:  2013-12-29       Impact factor: 5.790
  10 in total
  3 in total

1.  Successful and safe long-term treatment of cerebral aspergillosis with high-dose voriconazole guided by therapeutic drug monitoring.

Authors:  Pier Giorgio Cojutti; Maria Merelli; Lorenzo Allegri; Giuseppe Damante; Matteo Bassetti; Federico Pea
Journal:  Br J Clin Pharmacol       Date:  2018-11-09       Impact factor: 4.335

2.  High-Resolution Melting Assay for Genotyping Variants of the CYP2C19 Enzyme and Predicting Voriconazole Effectiveness.

Authors:  L Bernal-Martínez; L Alcazar Fuoli; B Miguel-Revilla; A Carvalho; M S Cuétara Garcia; J Garcia-Rodriguez; C Cunha; E Gómez-García de la Pedrosa; A Gomez-Lopez
Journal:  Antimicrob Agents Chemother       Date:  2019-05-24       Impact factor: 5.191

3.  Applying Pharmacogenomics to Antifungal Selection and Dosing: Are We There Yet?

Authors:  Matthew A Miller; Yee Ming Lee
Journal:  Curr Fungal Infect Rep       Date:  2020-01-16
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.